{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:05:10Z","timestamp":1780617910068,"version":"3.54.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":43,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A cluster-randomised cross-over trial assessing whether cephalosporin monotherapy is non-inferior to cefuroxime plus short-course aminoglycoside combination therapy for empirical sepsis treatment was terminated for operational futility due to low enrolment and low protocol adherence. We evaluated barriers to enrolment and treatment compliance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Trial enrolment was between May 2022 and May 2023. For this mixed-methods study, we used questionnaires to identify barriers to enrolment and prescribing randomised treatment among local research teams (LRTs) and local clinical staff, which were obtained between January and March 2024. In addition, we investigated screening logs for non-enrolment reasons and determined patient characteristics associated with non-compliance. Clinicians being part of LRT received questionnaires for both roles, with their role clearly indicated per question.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 65 questionnaires were completed: 23 by LRT members and 54 by clinical staff (including 12 LRT members). For patient enrolment, screening of inclusion and exclusion criteria was considered challenging in one hospital. According to screening logs, 52.2% of patients were excluded due to at least one exclusion criterion, and 15.6% of eligible patients declined consent for study participation. Primary barriers to prescribe combination therapy were concerns about potential side effects and limited perceived benefit compared to monotherapy. Secondary barriers included supervisors recommending deviations from study protocol. Keeping clinical staff informed and trained during the study was reported as relevant barrier for implementation by LRTs, but considered of low importance by clinical staff. No barriers were reported for monotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this study, the main barrier for patient enrolment was the higher than expected proportion of patients with exclusion criteria. The main barrier for treatment compliance was concerns about potential side effects of combination therapy. We recommend quantitative and qualitative pilot studies to identify barriers during the trial design phase, to optimise recruitment strategies and protocol adherence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      European Union Clinical Trials Register, EUCTR2021-001840-83-NL. Registered on 7 July 2021,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-001840-83\" ext-link-type=\"uri\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=eudract_number:2021-001840-83<\/jats:ext-link>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13063-026-09722-3","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T06:41:53Z","timestamp":1776926513000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Failure to rescue the trial: lessons from a randomised antibiotic treatment trial in the acute care setting"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-6839-9761","authenticated-orcid":false,"given":"Sharon E. J. D.","family":"van den Eijnde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva L.","family":"Koekenbier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"van der Linden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Jelrik","family":"Oosterheert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J. M.","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis H.","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the SAGA study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.S.M.","family":"Ammerlaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.R.","family":"Bouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.S.M.","family":"Dofferhoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gompelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.M.","family":"Kampschreur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"9722_CR1","doi-asserted-by":"publisher","unstructured":"International ethical guidelines for health-related research involving humans, fourth edition. Geneva. Council for International Organizations of Medical Sciences (CIOMS); 2016. https:\/\/doi.org\/10.56759\/rgxl7405","DOI":"10.56759\/rgxl7405"},{"key":"9722_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jeph.2024.202197","volume":"72","author":"B Giraudeau","year":"2024","unstructured":"Giraudeau B, Weijer C, Eldridge SM, Hemming K, Taljaard M. Why and when should we cluster randomize? J Epidemiol Popul Health. 2024;72:202197. https:\/\/doi.org\/10.1016\/j.jeph.2024.202197.","journal-title":"J Epidemiol Popul Health"},{"key":"9722_CR3","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1001\/jama.2016.0287","volume":"315","author":"M Singer","year":"2016","unstructured":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801\u201310. https:\/\/doi.org\/10.1001\/jama.2016.0287.","journal-title":"JAMA"},{"key":"9722_CR4","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1164\/rccm.201609-1848OC","volume":"196","author":"VX Liu","year":"2017","unstructured":"Liu VX, Fielding-Singh V, Greene JD, Baker JM, Iwashyna TJ, Bhattacharya J, et al. The timing of early antibiotics and hospital mortality in sepsis. Am J Respir Crit Care Med. 2017;196:856\u201363. https:\/\/doi.org\/10.1164\/rccm.201609-1848OC.","journal-title":"Am J Respir Crit Care Med"},{"key":"9722_CR5","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07653-3","volume":"22","author":"E Sieswerda","year":"2022","unstructured":"Sieswerda E, Bax HI, Hoogerwerf JJ, de Boer MGJ, Boermeester M, Bonten MJM, et al. The 2021 Dutch Working Party on Antibiotic Policy (SWAB) guidelines for empirical antibacterial therapy of sepsis in adults. BMC Infect Dis. 2022;22:687. https:\/\/doi.org\/10.1186\/s12879-022-07653-3.","journal-title":"BMC Infect Dis"},{"key":"9722_CR6","doi-asserted-by":"publisher","first-page":"e0217951","DOI":"10.1371\/journal.pone.0217951","volume":"14","author":"M Tanaka","year":"2019","unstructured":"Tanaka M, Hasegawa S, Nakao S, Shimada K, Mukai R, Matsumoto K, et al. Analysis of drug-induced hearing loss by using a spontaneous reporting system database. PLoS ONE. 2019;14:e0217951. https:\/\/doi.org\/10.1371\/journal.pone.0217951.","journal-title":"PLoS ONE"},{"key":"9722_CR7","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/cid\/cix186","volume":"64","author":"DSY Ong","year":"2017","unstructured":"Ong DSY, Frencken JF, Klein Klouwenberg PMC, Juffermans N, van der Poll T, Bonten MJM, et al. Short-course adjunctive gentamicin as empirical therapy in patients with severe sepsis and septic shock: a prospective observational cohort study. Clin Infect Dis. 2017;64:1731\u20136. https:\/\/doi.org\/10.1093\/cid\/cix186.","journal-title":"Clin Infect Dis"},{"key":"9722_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmicom.2025.105075","author":"EL Koekenbier","year":"2025","unstructured":"Koekenbier EL, van den Eijnde SEJD, van der Linden PD, Oosterheert JJ, Sieswerda E, Vintcent LEM, et al. Short-course aminoglycosides as adjunctive treatment in adults with sepsis: a post-hoc analysis of a prematurely terminated cluster randomized trial. CMI Commun. 2025. https:\/\/doi.org\/10.1016\/j.cmicom.2025.105075.","journal-title":"CMI Commun"},{"key":"9722_CR9","doi-asserted-by":"publisher","first-page":"e2524440","DOI":"10.1001\/jamanetworkopen.2025.24440","volume":"8","author":"B Speich","year":"2025","unstructured":"Speich B, TajiHeravi A, Sch\u00f6nenberger CM, et al. Nonregistration, discontinuation, and nonpublication of randomized trials: a systematic review. JAMA Netw Open. 2025;8:e2524440. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.24440.","journal-title":"JAMA Netw Open"},{"key":"9722_CR10","doi-asserted-by":"publisher","first-page":"507","DOI":"10.2307\/2531201","volume":"42","author":"JM Lachin","year":"1986","unstructured":"Lachin JM, Foulkes MA. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics. 1986;42:507\u201319.","journal-title":"Biometrics"},{"key":"9722_CR11","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1177\/1740774518761666","volume":"15","author":"SC Agbla","year":"2018","unstructured":"Agbla SC, DiazOrdaz K. Reporting non-adherence in cluster randomised trials: a systematic review. Clin Trials. 2018;15:294\u2013304. https:\/\/doi.org\/10.1177\/1740774518761666.","journal-title":"Clin Trials"},{"key":"9722_CR12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1177\/17407745211001504","volume":"18","author":"A Weir","year":"2021","unstructured":"Weir A, Presseau J, Kitto S, Colman I, Hatcher S. Strategies for facilitating the delivery of cluster randomized trials in hospitals: a study informed by the CFIR-ERIC matching tool. Clin Trials. 2021;18:398\u2013407. https:\/\/doi.org\/10.1177\/17407745211001504.","journal-title":"Clin Trials"},{"key":"9722_CR13","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2023.20583","volume":"330","author":"ET Qian","year":"2023","unstructured":"Qian ET, Casey JD, Wright A, Wang L, Shotwell MS, Siemann JK, et al. Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial. JAMA. 2023;330:1557\u201367. https:\/\/doi.org\/10.1001\/jama.2023.20583.","journal-title":"JAMA"},{"key":"9722_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13012-022-01245-0","volume":"17","author":"LJ Damschroder","year":"2022","unstructured":"Damschroder LJ, Reardon CM, Opra Widerquist MA, Lowery J. The updated consolidated framework for implementation research based on user feedback. Implement Sci. 2022;17:75. https:\/\/doi.org\/10.1186\/s13012-022-01245-0.","journal-title":"Implement Sci"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-026-09722-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-026-09722-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:50:25Z","timestamp":1780617025000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13063-026-09722-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":14,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9722"],"URL":"https:\/\/doi.org\/10.1186\/s13063-026-09722-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7641001\/v1","asserted-by":"object"}]},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SE, EK, PL, JJO, MB and CW report financial support was provided by Netherlands Organisation for Health Research and Development. PL reports a relationship with AMR care network Noord Holland Flevoland that includes funding grants. PL reports a relationship with Dutch Working Party of Antimicrobial policies that includes board membership. MB reports a relationship with MSD Merck Sharp & Dohme AG that includes consulting or advisory and funding grants. MB reports a relationship with Sanofi that includes board membership and funding grants. MB reports a relationship with GSK that includes consulting or advisory and funding grants. MB reports a relationship with Atea Pharmaceuticals that includes funding grants. MB reports a relationship with Shionogi that includes consulting or advisory. CW reports a relationship with DaVolterra that includes funding grants. CW reports a relationship with bioM\u00e9rieux SA that includes funding grants. CW reports a relationship with LimmaTech that includes funding grants. CW reports a relationship with MSD Merck Sharp & Dohme AG that includes consulting or advisory and funding grants. CW reports a relationship with Sanofi-Pasteur that includes consulting or advisory.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"418"}}